The model was developed based on results of our previous studies11, 12, 13 as we were not aware of any studies investigating the influence of SNPs on outcome of gemcitabine/cisplatin treatment in MM, while ERCC1, RRM1, ERCC2 and XRCC1 were consistently identified as prediction factors in pancreatic or non-small cell lung cancer (NSCLC)20, 21. Here, ERCC2 is linked to Miyoshi myopathy.